Last reviewed · How we verify
Montelukast mixed with Loratadine
This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (loratadine) to reduce allergic inflammation and symptoms.
This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (loratadine) to reduce allergic inflammation and symptoms. Used for Allergic rhinitis, Asthma (mild to moderate persistent), Allergic conditions with concurrent asthma.
At a glance
| Generic name | Montelukast mixed with Loratadine |
|---|---|
| Sponsor | Innovacion y Desarrollo de Estrategias en Salud |
| Drug class | Leukotriene receptor antagonist / Antihistamine combination |
| Target | CysLT1 receptor (montelukast) and H1 receptor (loratadine) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Montelukast is a leukotriene receptor antagonist that inhibits cysteinyl leukotriene-mediated inflammation, while loratadine is a selective H1-receptor antagonist that blocks histamine-induced allergic responses. Together, they target complementary pathways in allergic and inflammatory cascade to provide dual anti-inflammatory and antihistamine effects.
Approved indications
- Allergic rhinitis
- Asthma (mild to moderate persistent)
- Allergic conditions with concurrent asthma
Common side effects
- Headache
- Somnolence
- Pharyngitis
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: